Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire

References

• Payson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am 2006;33:1-11
   PubMed Web of Science ®Google Scholar
• Gliklich RE, Leavy MB, Velentgas P, et al. Identification of Future Research Needs in the Comparative Management of Uterine Fibroid Disease A Report on the Priority-Setting Process, Preliminary Data Analysis, and Research Plan. Rockville, MD: Agency for Healthcare Research and Quality. 2011
   Google Scholar
• Gretz H, Bradley WH, Zakashansky K, et al. Patient clinical factors influencing use of hysterectomy in New York, 2001–2005. Am J Obstet Gynecol 2008;199:349.e341-5
   PubMed Web of Science ®Google Scholar
• Keshavarz H, Hillis SD, Kieke BA, et al. Hysterectomy surveillance – United States, 1994–1999. MMWR CDC Surveill Summ 2002;51:1-8
   Google Scholar
• Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007;87:725-36
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians Gynecologists. Choosing the route of hysterectomy for benign disease. ACOG Committee Opinion No. 444. Obstet Gynecol 2009;114:1156-8
   PubMedGoogle Scholar
• Bukulmez O, Doody KJ. Clinical features of myomas. Obstet Gynecol Clin North Am 2006;33:69-84
   PubMed Web of Science ®Google Scholar
• Stovall DW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001;44:364-71
   PubMed Web of Science ®Google Scholar
• Spies JB, Coyne K, Guaou NG, et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002;99:290-300
   PubMed Web of Science ®Google Scholar
• Coyne KS, Margolis MK, Bradley LD, et al. Further validation of the uterine fibroid symptom and quality-of-life questionnaire. Value Health 2012;15:135-42
   PubMed Web of Science ®Google Scholar
• Stull DE, Leidy NK, Parasuraman B, et al. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 2009;25:929-42
   PubMed Web of Science ®Google Scholar
• Norquist JM, Girman C, Fehnel S, et al. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res 2012;21:1013-20
   PubMed Web of Science ®Google Scholar
• Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. Womens Health Issues 2004;14:242-7
   PubMed Web of Science ®Google Scholar
• Hallberg L, Hôgdahl A-M, Nilsson L, et al. Menstrual blood loss – a population study: variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-51
   PubMed Web of Science ®Google Scholar
• Wyatt KM, Dimmock PW, Walker TJ, et al. Determination of total menstrual blood loss. Fertil Steril 2001;76:125-31
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009;74:65132-3
   Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334
   Web of Science ®Google Scholar
• Hays R, Revicki D. Reliability and validity, including responsiveness. In: Fayers P, Hays RD, eds. Assessing Quality of Life in Clinical Trials, 2nd edn. New York: Oxford University Press, 2005
   Google Scholar
• Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27(3Suppl):S178-S89
   Web of Science ®Google Scholar
• Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-78
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-73
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988
   Google Scholar
• De Cock VC, Bayard S, Jaussent I, et al. Daytime sleepiness in Parkinson’s disease: a reappraisal. PLoS One 2014;9:e107278
   PubMed Web of Science ®Google Scholar
• Gallizzi MA, Khazai RS, Gagnon CM, et al. Use of a medication quantification scale for comparison of pain medication usage in patients with complex regional pain syndrome (CRPS). Pain Med 2015;16:494-500
   PubMed Web of Science ®Google Scholar
• Song MK, Ward SE, Bair E, et al. Patient-reported cognitive functioning and daily functioning in chronic dialysis patients. Hemodialysis International 2015;19:90-9
   PubMed Web of Science ®Google Scholar
• Harding G, Coyne KS, Thompson CL, et al. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 2008;6:99
   PubMed Web of Science ®Google Scholar
• Spies JB, Myers ER, Worthington-Kirsch R, et al. The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol 2005;106:1309-18
   PubMed Web of Science ®Google Scholar
• Ware J, Snow K, Kosinski M, et al. SF-36 Health Survey: manual and interpretation guide. Boston, MA: The Health Institute, 1993
   Google Scholar
• Keller SD, Bayliss MS, Ware Jr JE, et al. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res 1997;32:367
   PubMed Web of Science ®Google Scholar
• Revicki DA, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994;32:401-4
   PubMed Web of Science ®Google Scholar
• Coyne KS, Gelhorn H, Thompson C, et al. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J 2011;22:1555-63
   PubMed Web of Science ®Google Scholar